Biotech and Pharmaceuticals
2026 is the year of obesity pills. Here’s how they could reshape the GLP-1 market
The booming GLP-1 space was built on weekly injections. In 2026, new obesity pills will push the market into its next chapter. Patients are already getting their hands on the first GLP-1 pill for obesity from Danish drugmaker Novo Nordisk — a once-daily drug that shares the same brand name as its popular injection Wegovy. […]
Read More
Gen Z and social media are helping men’s makeup go mainstream. The beauty industry is trying to capitalize
Pixdeluxe | E+ | Getty Images It often starts small. A dab of concealer. A tinted moisturizer. Maybe a brow gel that goes from borrowed to bought. For many men, like Daniel Rankin, makeup has transformed from something taboo into a tool to make them look less tired and more put together. “I remember thinking, […]
Read More
Healthy Returns: What to expect from pharma at the JPM conference
Heidi Overton, Novo Nordisk CEO Maziar Mike Doustdar, Eli Lilly CEO David A. Ricks, and U.S. Secretary of Commerce Howard Lutnick listen while U.S. President Donald Trump announces a deal with Eli Lilly and Novo Nordisk on to reduce the prices of GLP-1 weight‑loss drugs during an event in the Oval Office at the White […]
Read More
A little-known biotech stock has become a prime takeover target after surging nearly 1,700% last year
Europe’s best-performing blue-chip stock in 2025 is widely expected to be bought by a larger peer, in a deal analysts say could be worth as much as $23 billion. Abivax, the French clinical-stage biotech company developing a treatment for ulcerative colitis and Crohn’s disease, saw shares rocket 1,681% last year, far outpacing the Stoxx 600 […]
Read More
Big Pharma race to snap up biotech assets as $170 billion patent cliff looms
Two employees in pharmaceutical industry wearing protective gloves, mask, cap and white suit seen standing by the machine that is the part of the medicaments production during the working hours in a pharmaceutical manufacturing. Extreme-photographer | E+ | Getty Images A multitude of factors are coming together to bring a big burst in biotech M&A. […]
Read More
First GLP-1 pill for obesity from Novo Nordisk launches in the U.S.
The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, on the outskirts of Copenhagen, Nov. 24, 2025. Tom Little | Reuters Novo Nordisk will start rolling out the first-ever GLP-1 pill for weight loss in the U.S. on Monday, the company announced, marking a new chapter of obesity […]
Read More
Novo Nordisk enters 2026 on the defense as it faces a ‘must-win’ battle in the U.S. market
Still life of the big three injectable prescription weight loss medicines. Ozempic, Victoza and Wegovy. (Photo by: Michael Siluk/UCG/Universal Images Group via Getty Images) Ucg | Universal Images Group | Getty Images Novo Nordisk’s shift from a market darling to a serious underperformer has set the stage for a transitional 2026 as the Danish drugmaker […]
Read More
Novo Nordisk’s ‘long game’ on weight loss drugs sparks hope in science, but the Street is impatient
Ozempic is medicine for adults with type 2 diabetes that along with diet and exercise may improve blood sugar. (Photo by Steve Christo – Corbis/Corbis via Getty Images) Steve Christo – Corbis | Corbis News | Getty Images Novo Nordisk has had a difficult year: a tumbling stock price resulting in the biggest leadership shakeup […]
Read More
FDA approves first GLP-1 pill for obesity from Wegovy maker Novo Nordisk
The logo of pharmaceutical company Novo Nordisk is displayed in front of its offices in Bagsvaerd, on the outskirts of Copenhagen, Denmark, Nov. 24, 2025. Tom Little | Reuters The U.S. Food and Drug Administration on Monday approved the first-ever GLP-1 pill for obesity from Wegovy maker Novo Nordisk, a landmark decision that health experts […]
Read More
Nine of the largest pharma companies ink deals with Trump to lower drug prices
President Donald Trump signs an executive order aimed at reducing the cost of prescription drugs and pharmaceuticals by 30% to 80% during an event in the Roosevelt Room of the White House on May 12, 2025, in Washington, DC. Andrew Harnik | Getty Images Several of the largest U.S. and European-based drugmakers inked deals with […]
Read More